Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
negativeNegative
AI Analysis
Summary
Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis resulted in a patient death in November 2025, raising serious safety concerns regarding the therapeutic approach.
Outcome Details
Patient death reported in November 2025 following administration of investigational ATTR gene therapy
Importance:8/10
Sentiment:
-0.85
safetygene therapyATTR amyloidosisadverse eventpatient death
Related Companies
Read the original article
Published by BioSpace on August 7, 2026 12:48 PM